OSCRHealthcare · Healthcare PlansThe 11 Wall Street analysts covering Oscar Health, Inc. hold a median 12-month price target of $34 — -0.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 14 Oct 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Oscar Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (97): The shares have been drifting up relative to others.
Issuance (23): The company has been issuing shares or taking on financing, diluting existing holders.
Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on OSCR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −0.9% from it.
Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Sept 2026 | Raymond James | Maintains | Outperform | $34 → $42 |
| 17 Sept 2026 | B of A Securities | Maintains | Underperform | $28 → $30 |
| 17 Sept 2026 | Baird | Maintains | Neutral | $27 → $33 |
| 17 Sept 2026 | Barclays | Maintains | Overweight | $39 → $49 |
| 17 Sept 2026 | Stephens & Co. | Reiterates | Equal-Weight | $34 |
| 13 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 13 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $20 → $27 |
| 7 Aug 2026 | Barclays | Maintains | Overweight | — |
| 7 Aug 2026 | Barclays | Maintains | Overweight | $35 → $39 |
| 7 Aug 2026 | UBS | Maintains | Neutral | $20 → $26 |
| 7 Aug 2026 | UBS | Maintains | Neutral | — |
| 10 June 2026 | Barclays | Upgrade | Overweight | — |
| 10 June 2026 | Barclays | Upgrade | Overweight | $30 → $35 |
| 26 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 7 May 2026 | Baird | Maintains | Neutral | — |
| 7 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 7 May 2026 | UBS | Maintains | Neutral | — |
| 6 May 2026 | Wolfe Research | Initiates | Peer Perform | — |
| 20 Apr 2026 | Jefferies | Upgrade | Hold | — |
| 9 Jan 2026 | UBS | Upgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OSCR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Oscar Health, Inc. returned +65.9% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 29% of US stocks
Cheaper than 76% of US stocks
Cheaper than 19% of US stocks
Cheaper than 55% of US stocks
Higher than 90% of US stocks
Higher than 79% of US stocks
Higher than 60% of US stocks
Higher than 57% of US stocks
Higher than 89% of US stocks
Higher than 73% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Oscar Health, Inc. has a market value of $10.4B and an enterprise value of $2.3B.
Revenue in the twelve months to 30 June 2026: $15.3B. The latest quarter grew 70.4% year on year.
Net income over the same four quarters: $550.9M, a 3.6% net margin.
Diluted earnings per share, trailing twelve months: $1.40.
Free cash flow in the twelve months to 30 June 2026: $4.4B.
Trailing P/E: 26.2×; forward P/E: 15.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Oscar Health, Inc. employs 2,305 people — $6.6M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Oscar Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research listed Oscar Health (OSCR), alongside WOOF and FIVE, among its Zacks Rank #1 (Strong Buy) growth stocks on October 13, 52026.
Why it matters — The item notes OSCR's inclusion on Zacks' list of growth stocks with a #1 ranking.
Oscar Health closed at $34.32 in the most recent trading session, up 1.57% from the previous trading day.
Why it matters — OSCR watchers may note the stock’s daily gain amid a market decline, as indicated by the headline.
A Zacks Investment Research headline describes Oscar Health as a top-ranked momentum stock. The excerpt says Zacks Style Scores are a feature of its Premium research service for identifying stocks across value, growth, and momentum styles.
Why it matters — OSCR watchers may note the headline’s momentum framing and the reference to Zacks’ stock-rating research feature.
Zacks Investment Research says Oscar Health passed its “Fast-Paced Momentum at a Bargain” screen, which identifies stocks with recent momentum that it considers reasonably priced.
Why it matters — The item presents OSCR as matching a screen focused on recent share momentum and valuation.
Zacks Investment Research says Oscar Health’s revenue and membership gains, along with improving profitability, support its growth story. It also notes that a premium valuation and churn risks cloud the outlook.
Why it matters — OSCR watchers may weigh the reported growth and profitability progress against valuation and membership-retention concerns.
The 11 Wall Street analysts covering Oscar Health, Inc. have a median 12-month price target of $34, with estimates ranging from $27 to $49. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Oscar Health, Inc., 3 rate it a Buy, 7 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Oscar Health, Inc. 91 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Oscar Health, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies -0.9% from the last close, and Ticker Nerd's factor model ranks Oscar Health, Inc. 91 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Oscar Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OSCR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $27 to $49 over the next 12 months.
Oscar Health, Inc. returned +65.9% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Oscar Health, Inc. Class A Common Stock represents ownership in Oscar Health, a healthcare technology company focused on health insurance products and digital member services in the United States.
The most recent item we track (Zacks Investment Research, 15 Oct 2026): "Best Growth Stocks to Buy for October 15th". Zacks Investment Research listed Oscar Health (OSCR), alongside WOOF and FIVE, among its Zacks Rank #1 (Strong Buy) growth stocks on October 13, 52026.
Oscar Health, Inc. Class A Common Stock represents ownership in Oscar Health, a healthcare technology company focused on health insurance products and digital member services in the United States. Oscar Health combines insurance coverage with a technology platform designed to help members access care, manage plans, and navigate the healthcare system. Its current offerings include individual and family health plans, small group coverage, and Medicare Advantage plans, along with technology solutions for providers and payors. The company operates in the managed health care and health services space, where it serves consumers and business customers through a data-driven, consumer-oriented model. Headquartered in New York, Oscar Health is positioned as a modern health insurer that integrates software, service, and clinical support across its insurance operations.
CEO Mr. Mark Thomas Bertolini · 2,305 employees · United States · https://www.hioscar.com
